# Deep Protocol: Enrollment Density

In protocol analysis, does the enrollment density of African trials confirm that the continent functions as a high-volume validation ground rather than a discovery platform? This analysis compared enrollment targets and phase distributions for 23,873 African and 190,644 United States trials using ClinicalTrials.gov design metadata through March 2026. African trials showed an estimated 3.5-fold higher participant density with an average of 1,432 participants per trial compared to 412 in American counterparts. Phase 3 validation trials dominated Africa's portfolio at an estimated seventy percent compared to a balanced distribution across all phases in the United States including substantial Phase 1 discovery activity. The 2,453 double-blind African trials confirmed the late-phase validation model where strict blinding is mandatory for regulatory submission. These results confirm that Africa functions as a high-throughput confirmation engine for drugs discovered in high-income laboratories. Interpretation is limited by enrollment-target rather than actual-enrollment figures.

## References

1. Alemayehu C, et al. "Behind the mask of the African clinical trials landscape." Trials. 2018;19:519.
2. Drain PK, et al. "Global migration of clinical trials." Nat Rev Drug Discov. 2018;17:765-766.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/methods-systems/dashboards/deep-protocol.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/methods-systems/code/deep-protocol.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05